Lynn McRoy
About
Lynn McRoy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Lynn McRoy has authored 50 papers receiving a total of 617 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 21 papers in Cancer Research. Recurrent topics in Lynn McRoy's work include Advanced Breast Cancer Therapies (45 papers), Breast Cancer Treatment Studies (20 papers) and HER2/EGFR in Cancer Research (15 papers). Lynn McRoy is often cited by papers focused on Advanced Breast Cancer Therapies (45 papers), Breast Cancer Treatment Studies (20 papers) and HER2/EGFR in Cancer Research (15 papers). Lynn McRoy collaborates with scholars based in United States, Italy and Germany. Lynn McRoy's co-authors include Adam Brufsky, Xianchen Liu, Rachel M. Layman, Hope S. Rugo, Benjamin Li, Richard S. Finn, Massimo Cristofanilli, Angela DeMichele, Mylin A. Torres and Jack Mardekian and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.
In The Last Decade
Lynn McRoy
46 papers receiving 608 citations
Peers
Lynn McRoy
David Chandiwana United States
Joanne Cox United States
Amin Haiderali United States
M. Corona Gainford Canada
Katherine B. Winfree United States
Mark L. Zangardi United States
O. Rixe France
Sandeep Sehdev Canada
Shengchun Kong United States
Valerie Bée United States
Citations per year, relative to Lynn McRoy Lynn McRoy (= 1×)
peers
David Chandiwana
Countries citing papers authored by Lynn McRoy
Since
Specialization
Citations
This map shows the geographic impact of Lynn McRoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lynn McRoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lynn McRoy more than expected).
Fields of papers citing papers by Lynn McRoy
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lynn McRoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lynn McRoy. The network helps show where Lynn McRoy may publish in the future.
Co-authorship network of co-authors of Lynn McRoy
This figure shows the co-authorship network connecting the top 25 collaborators of Lynn McRoy. A scholar is included among the top collaborators of Lynn McRoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lynn McRoy. Lynn McRoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Rugo, Hope S., Rachel M. Layman, Filipa Lynce, et al.. (2025). Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice. ESMO Open. 10(9). 105570–105570.
2.
Robert, Nicholas J., Connie Chen, Sindy Kim, et al.. (2024). Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. Future Oncology. 20(12). 761–780.
3.
Rugo, Hope S., Xianchen Liu, Benjamin Li, et al.. (2024). Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study. Future Oncology. 20(19). 1299–1307.
4.
Rugo, Hope S., Xianchen Liu, Benjamin Li, et al.. (2023). Real‐world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database. International Journal of Cancer. 154(4). 701–711.
5.
Brufsky, Adam, et al.. (2023). 223P Real-world effectiveness of palbociclib (Pal) plus an aromatase inhibitor (AI) vs AI alone in patients who have metastatic breast cancer (mBC) with lung or liver metastases. ESMO Open. 8(1). 101412–101412.
6.
Liu, Xianchen, et al.. (2023). Financial Toxicity among Patients with Breast Cancer during the COVID-19 Pandemic in the United States. Cancers. 16(1). 62–62.
7.
Liu, Xianchen, Alexandra Berk, Marisa C. Weiss, et al.. (2023). Psychosocial Wellbeing among Patients with Breast Cancer during COVID-19. Current Oncology. 30(4). 3886–3900.
8.
Brufsky, Adam, Xianchen Liu, Benjamin Li, et al.. (2023). Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older. Frontiers in Oncology. 13. 1237751–1237751.
9.
DeMichele, Angela, Nicholas J. Robert, Connie Chen, et al.. (2023). Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer. Targeted Oncology. 18(4). 543–558.
10.
Brufsky, Adam, Xianchen Liu, Benjamin Li, et al.. (2023). Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice. Cancers. 15(21). 5268–5268.
11.
Rugo, Hope S., Adam Brufsky, Xianchen Liu, et al.. (2023). Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary. Future Oncology. 19(7). 489–498.
12.
Patt, Debra A., Xianchen Liu, Benjamin Li, et al.. (2022). Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. Clinical Breast Cancer. 22(6). 601–610.
13.
Rugo, H. S., Adam Brufsky, Lynn McRoy, et al.. (2022). 169P Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis. Annals of Oncology. 33. S202–S202.
14.
Brufsky, Adam, Xianchen Liu, Benjamin Li, Lynn McRoy, & Rachel M. Layman. (2022). Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis. Frontiers in Oncology. 12. 865292–865292.
15.
Rugo, Hope S., Adam Brufsky, Xianchen Liu, et al.. (2022). Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer. npj Breast Cancer. 8(1). 114–114.
16.
Rugo, Hope S., Massimo Cristofanilli, Sybille Loibl, et al.. (2021). Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. The Oncologist. 26(8). e1339–e1346.
17.
Brufsky, Adam, et al.. (2020). 176P Real-world tumour response of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US clinical practices. Annals of Oncology. 31. S79–S79.
18.
Finn, Richard S., Katalin Boér, Igor Bondarenko, et al.. (2020). Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18). Breast Cancer Research and Treatment. 183(2). 419–428.
19.
Liu, Xianchen, et al.. (2020). <p>Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best–Worst Scaling</p>. Patient Preference and Adherence. Volume 14. 2201–2214.
20.
Brufsky, Adam, Debanjali Mitra, Keith L. Davis, et al.. (2019). Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2− Advanced Breast Cancer Enrolled in an Expanded Access Program. Clinical Breast Cancer. 19(5). 317–325.e4.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by David Chandiwana Breakdown of academic impact, for papers by Joanne Cox Breakdown of academic impact, for papers by Amin Haiderali Breakdown of academic impact, for papers by M. Corona Gainford Breakdown of academic impact, for papers by Katherine B. Winfree Breakdown of academic impact, for papers by Mark L. Zangardi Breakdown of academic impact, for papers by O. Rixe Breakdown of academic impact, for papers by Sandeep Sehdev Breakdown of academic impact, for papers by Shengchun Kong Breakdown of academic impact, for papers by Valerie Bée